AVITA Medical, Inc.

AVITA Medical, Inc. is a commercial-stage regenerative medicine company dedicated to acute wound care and skin restoration. The company's mission centers on transforming lives through innovative skin healing technologies, aiming to optimize wound healing and accelerate patient recovery. Its principal executive offices are located in Valencia, California, United States.

At the forefront of AVITA Medical's product portfolio is the RECELL System, an FDA-approved device that utilizes a small sample of a patient's own skin to generate "Spray-On Skin" cells. This technology is used for the treatment of thermal burn wounds, full-thickness skin defects, and for the repigmentation of stable depigmented vitiligo lesions. In the United States, AVITA Medical also holds exclusive rights to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix, and Cohealyx, an AVITA Medical-branded collagen-based dermal matrix. Globally, the RECELL System is approved for various applications, including thermal burn and trauma wounds, and holds CE-mark approval in Europe, TGA certification in Australia, and PMDA approval in Japan.

Recent leadership changes saw Cary Vance appointed as President and Chief Executive Officer in April 2026, with Jan Stern Reed named Chair of the Board. The company also secured a 10-year agreement, valued at up to $25.5 million, with the Biomedical Advanced Research and Development Authority (BARDA) under Project BioShield. This agreement aims to bolster national preparedness for burn mass casualty incidents. AVITA Medical maintains its position as a leading therapeutic acute wound care company, focused on expanding its market presence and product offerings.

Latest updates

AVITA Medical Appoints Interim CEO Vance Permanently, Names New Board Chair

Event summary

  • Cary Vance has been appointed President and CEO of AVITA Medical, effective immediately, following a six-month interim tenure.
  • Jan Stern Reed has been elected Chair of the AVITA Medical Board of Directors, replacing the previous Lead Independent Director role.
  • The appointment of Vance was made after a search process coordinated with an international executive search firm.
  • Vance previously served on the Board since 2023 and as Chairman in 2025.
  • AVITA Medical will host an earnings call on May 14, 2026, to discuss first-quarter 2026 results.

The big picture

The appointment of Vance suggests a desire for stability and accelerated growth following a period of transition. His experience commercializing medical technologies could be valuable, but also raises questions about his past performance. The Board's decision to appoint an external CEO, rather than promoting from within, signals a potential need for a fresh perspective and a more aggressive growth strategy in a competitive wound care market.

What we're watching

Execution Risk
Vance’s track record of leadership at multiple prior companies, while extensive, also includes several that did not achieve sustained success; the market will scrutinize his ability to translate momentum into consistent financial performance.
Market Adoption
The company’s stated focus on scaling adoption of RECELL and related products will be critical; the pace of clinician onboarding and integration into treatment protocols will directly impact revenue growth.
Governance Dynamics
With a new Chair and permanent CEO, the Board’s influence on strategic direction will be tested; the alignment of Vance’s vision with the Board’s priorities will shape the company’s long-term trajectory.

AVITA Medical Secures Regulatory Approvals for RECELL GO in Australia, New Zealand

Event summary

  • AVITA Medical received TGA certification in Australia and WAND listing in New Zealand for RECELL GO, its automated Spray-On Skin preparation system.
  • Revolution Surgical, AVITA’s distribution partner, anticipates a commercial launch within the coming weeks.
  • RECELL GO automates the preparation of RECELL Spray-On Skin, reducing operator variability and complexity.
  • The system treats wounds up to 1,920 cm2 with a single preparation kit.
  • RECELL was originally developed in Australia by Professor Fiona Wood and is now approved in the U.S., Europe, U.K., Australia, New Zealand, and Japan.

The big picture

The regulatory approvals for RECELL GO represent a significant step for AVITA Medical, solidifying its position in the acute wound care market. The move towards automation and standardization of skin cell preparation addresses a key pain point for clinicians, potentially improving patient outcomes and reducing costs. The partnership with Revolution Surgical will be crucial for driving adoption and market penetration in the Australian and New Zealand markets, which collectively represent a meaningful, albeit geographically concentrated, opportunity.

What we're watching

Market Adoption
The speed of commercial adoption in Australia and New Zealand will be a key indicator of RECELL GO’s value proposition and Revolution Surgical’s effectiveness as a distribution partner.
Competitive Landscape
How AVITA Medical’s standardized process and reduced operator burden will affect the competitive dynamics within the acute wound care market, particularly against alternative skin grafting methods, warrants close observation.
Expansion Strategy
The success in Australia and New Zealand will likely inform AVITA Medical’s strategy for expanding RECELL GO’s availability in other international markets.
CID: 820